Skip to content

Chronic Disease

Chronic Disease

Top Stories View All

Journal Article

Proposal for a Value-Based Agreement to Reimburse Anti-Obesity Medicines in Traditional Medicare

Abstract Anti-obesity medicines (AOMs), such as glucagon-like peptide-1 (GLP-1) agonists, hold great promise for slowing the chronic disease epidemic in the United States. Treatment with semaglutide and tirzepatide produces substantial weight loss and significant reductions in obesity-related diseases. Prior research shows expanding access to AOMs would generate trillions of dollars in social value to Americans…

Featured Experts: Alison Sexton Ward, Erin Trish, Dana Goldman, Darius Lakdawalla